Skin News

Thursday, March 27, 2008 Diabetes Drugs May Prevent Psoriasis
Diabetes drugs such as Avandia^® and Actos^® may reduce the risk of developing psoriasis…

Tuesday, February 05, 2008 Centocor Announces Ustekinumab (CNTO 1275) Biologics License Application Accepted by US FDA for the Treatment of Psoriasis
Centocor, Inc announced that the Biologics License Application for ustekinumab (CNTO 1275), a fully-human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, has been accepted for review by the US FDA for the treatment of chronic moderate-to-severe plaque psoriasis in adults...

Monday, February 04, 2008 Amgen, Wyeth Report Enbrel® (etanercept) Significantly Reduced Levels of CRP, a Marker of Inflammation, in Patients with Moderate-to-Severe Plaque Psoriasis
Amgen Inc and Wyeth Pharmaceuticals announced findings from a retrospective analysis demonstrating that Enbrel® (etanercept), a fully human soluble TNF receptor, reduced C-reactive protein (CRP) in patients with moderate-to-severe plaque psoriasis...

Tuesday, January 29, 2008 Association Between Psoriasis and the Metabolic Syndrome
Researchers have found a possible association between psoriasis and the metabolic syndrome, and have suggested possible new treatment options for the management of psoriasis...

Thursday, January 24, 2008 Characteristic Electron Microscopic Findings in the Skin of Patients With Fibromyalgia
The lower pain threshold of fibromyalgia patients may be caused by abnormal unmyelinated nerve fibers and associated Schwann cells...

Wednesday, January 23, 2008 Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...

Tuesday, January 22, 2008 Four Research Groups Report New Lupus Genes
A major international collaborative that includes European and North American lupus researchers, government agencies, research foundations, and industry has discovered four new lupus-related genes and may increase interest in the B-cell-receptor signaling pathway and in inflammatory cell adhesion as potential therapeutic targets...

Tuesday, January 22, 2008 Dermal Mucin in Alopecia Areata - Tell Tale Sign or Incidental Finding?
Dermal deposition of mucin may serve as a clue for diagnosing lupus in alopecia patients… 

Tuesday, January 22, 2008 New Jersey Investigating Amgen's Marketing of a Psoriasis Drug
New Jersey's attorney general is investigating biotechnology company Amgen Inc over possible patient confidentiality law violations in their efforts to sell Enbrel®â€¦

Wednesday, January 16, 2008 Incyte Reports INCB18424, a Selective JAK2 Inhibitor, Shows Initial Positive Clinical Activity With Rapid Onset of Action in RA and Psoriasis
Incyte Corp announced positive clinical proof-of-concept results with its wholly-owned, internally developed, lead JAK2 (Janus-associated kinase 2) inhibitor, INCB18424, in rheumatoid arthritis (RA) and psoriasis...